Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?
Mariëtte E.G. Kranendonk(Princess Máxima Center), Sabine Plasschaert(Princess Máxima Center), Bastiaan B.J. Tops(Radboud University Nijmegen), Dannis G. van Vuurden(Amsterdam UMC Location Vrije Universiteit Amsterdam), Eelco W. Hoving(Princess Máxima Center), Pieter Wesseling(Radboud University Nijmegen), Thijs J M van den Broek(Princess Máxima Center), Lennart Kester(Royal Netherlands Academy of Arts and Sciences), Jasper van der Lugt(Princess Máxima Center), Julie A S Lammers(Princess Máxima Center), Nelleke Tolboom(Utrecht University), Raoull Hoogendijk, Ella de Boed(Princess Máxima Center), Esther van Mastrigt(Princess Máxima Center)
Cited by 6
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
<scp>WHO</scp> 2016 Classification of gliomas
|Neuropathology and Applied Neurobiology|2017|817
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Diffuse glioma growth: a guerilla war
|Acta Neuropathologica|2007|640